| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dronabinol | 15 | 2014 | 31 | 2.600 |
Why?
|
| Cannabinoids | 9 | 2016 | 41 | 1.880 |
Why?
|
| Anti-Inflammatory Agents | 9 | 2016 | 169 | 1.450 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 9 | 2016 | 202 | 1.330 |
Why?
|
| gamma-Linolenic Acid | 14 | 2002 | 16 | 1.060 |
Why?
|
| Arthritis, Rheumatoid | 20 | 2008 | 348 | 0.980 |
Why?
|
| Inflammation | 12 | 2016 | 1196 | 0.980 |
Why?
|
| Interleukin-1 | 9 | 2003 | 154 | 0.930 |
Why?
|
| Monocytes | 10 | 2008 | 362 | 0.890 |
Why?
|
| Endocannabinoids | 4 | 2016 | 23 | 0.850 |
Why?
|
| Synovial Membrane | 6 | 2008 | 21 | 0.770 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2008 | 248 | 0.590 |
Why?
|
| Eicosanoids | 8 | 2009 | 25 | 0.570 |
Why?
|
| Synovial Fluid | 8 | 2008 | 29 | 0.560 |
Why?
|
| T-Lymphocytes | 9 | 2003 | 1013 | 0.530 |
Why?
|
| Fatty Acids | 9 | 2007 | 200 | 0.510 |
Why?
|
| Arachidonic Acids | 5 | 2009 | 27 | 0.500 |
Why?
|
| Prostaglandins | 7 | 2008 | 18 | 0.480 |
Why?
|
| Fibrosis | 1 | 2016 | 172 | 0.460 |
Why?
|
| Analgesics | 3 | 2007 | 102 | 0.420 |
Why?
|
| Plant Oils | 6 | 2009 | 66 | 0.410 |
Why?
|
| Cells, Cultured | 17 | 2008 | 2192 | 0.390 |
Why?
|
| Lymphocyte Activation | 7 | 2008 | 755 | 0.380 |
Why?
|
| PPAR gamma | 3 | 2007 | 77 | 0.370 |
Why?
|
| Fatty Acids, Unsaturated | 4 | 1999 | 28 | 0.360 |
Why?
|
| Antirheumatic Agents | 3 | 2007 | 228 | 0.350 |
Why?
|
| Pain | 2 | 2004 | 400 | 0.350 |
Why?
|
| Cannabinoid Receptor Modulators | 2 | 2009 | 8 | 0.340 |
Why?
|
| Cannabis | 4 | 2009 | 54 | 0.330 |
Why?
|
| Apoptosis | 2 | 2008 | 1099 | 0.320 |
Why?
|
| Glycine | 3 | 2009 | 49 | 0.320 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2007 | 605 | 0.300 |
Why?
|
| Rheumatic Diseases | 2 | 2002 | 42 | 0.300 |
Why?
|
| Fibroblasts | 3 | 2009 | 423 | 0.300 |
Why?
|
| Macrophages | 5 | 2008 | 1042 | 0.300 |
Why?
|
| Arachidonic Acid | 6 | 2008 | 38 | 0.290 |
Why?
|
| Lipoxins | 1 | 2009 | 7 | 0.290 |
Why?
|
| Arthritis, Experimental | 5 | 2007 | 30 | 0.280 |
Why?
|
| Psychotropic Drugs | 3 | 2008 | 81 | 0.280 |
Why?
|
| Osteoclasts | 1 | 2008 | 53 | 0.270 |
Why?
|
| Arthritis | 3 | 2005 | 53 | 0.260 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2007 | 7 | 0.250 |
Why?
|
| Linolenic Acids | 4 | 1991 | 6 | 0.250 |
Why?
|
| Humans | 49 | 2016 | 65872 | 0.240 |
Why?
|
| Animals | 22 | 2016 | 21494 | 0.240 |
Why?
|
| Eicosapentaenoic Acid | 3 | 1997 | 18 | 0.230 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 6 | 1999 | 21 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2014 | 859 | 0.220 |
Why?
|
| Cannabidiol | 1 | 2004 | 3 | 0.220 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2004 | 9 | 0.220 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1391 | 0.210 |
Why?
|
| Rats | 11 | 2009 | 2005 | 0.210 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 1997 | 21 | 0.200 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2003 | 29 | 0.200 |
Why?
|
| Cyclooxygenase 2 | 4 | 2008 | 62 | 0.200 |
Why?
|
| RNA, Messenger | 6 | 2008 | 1584 | 0.180 |
Why?
|
| Eicosanoic Acids | 2 | 1994 | 3 | 0.180 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 20 | 0.180 |
Why?
|
| Mice | 11 | 2014 | 11183 | 0.180 |
Why?
|
| Knee Joint | 1 | 2005 | 312 | 0.180 |
Why?
|
| Liver Diseases | 1 | 2002 | 157 | 0.170 |
Why?
|
| Adjuvants, Immunologic | 4 | 2000 | 238 | 0.160 |
Why?
|
| Prostaglandins E | 4 | 1991 | 8 | 0.150 |
Why?
|
| Receptor, Cannabinoid, CB2 | 2 | 2014 | 11 | 0.150 |
Why?
|
| Interleukin-8 | 3 | 2005 | 96 | 0.150 |
Why?
|
| Dinoprostone | 3 | 1994 | 42 | 0.140 |
Why?
|
| In Vitro Techniques | 4 | 2003 | 491 | 0.140 |
Why?
|
| Cell Division | 3 | 2003 | 451 | 0.140 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2009 | 95 | 0.130 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2005 | 20 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1999 | 282 | 0.130 |
Why?
|
| Fish Oils | 2 | 1995 | 43 | 0.130 |
Why?
|
| Administration, Oral | 4 | 2002 | 370 | 0.120 |
Why?
|
| Interleukin-2 | 3 | 1994 | 167 | 0.120 |
Why?
|
| Disease Models, Animal | 5 | 2009 | 2327 | 0.120 |
Why?
|
| Phospholipases | 2 | 1986 | 9 | 0.120 |
Why?
|
| Phospholipases A | 2 | 1986 | 15 | 0.120 |
Why?
|
| Type C Phospholipases | 2 | 1986 | 34 | 0.120 |
Why?
|
| Arthritis, Psoriatic | 2 | 2008 | 32 | 0.110 |
Why?
|
| Protein Kinase C | 1 | 1995 | 102 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2008 | 1045 | 0.110 |
Why?
|
| Interleukin-6 | 2 | 2007 | 324 | 0.110 |
Why?
|
| Immune System | 1 | 1995 | 133 | 0.100 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2014 | 15 | 0.100 |
Why?
|
| Neutrophils | 2 | 2009 | 396 | 0.100 |
Why?
|
| Liposomes | 1 | 1994 | 117 | 0.100 |
Why?
|
| Gene Expression | 4 | 2005 | 858 | 0.100 |
Why?
|
| Immunity, Cellular | 2 | 1993 | 170 | 0.100 |
Why?
|
| Receptors, Cannabinoid | 3 | 2009 | 7 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1994 | 241 | 0.100 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2004 | 151 | 0.090 |
Why?
|
| Male | 14 | 2009 | 31435 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 390 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2003 | 315 | 0.090 |
Why?
|
| Cell Survival | 3 | 1999 | 588 | 0.090 |
Why?
|
| Polyunsaturated Alkamides | 2 | 2002 | 6 | 0.090 |
Why?
|
| Chemotactic Factors | 1 | 1991 | 25 | 0.080 |
Why?
|
| Membrane Proteins | 3 | 2005 | 930 | 0.080 |
Why?
|
| Antibody Formation | 1 | 1991 | 111 | 0.080 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 357 | 0.080 |
Why?
|
| Synovitis | 4 | 1999 | 30 | 0.080 |
Why?
|
| Acute-Phase Reaction | 1 | 1989 | 18 | 0.070 |
Why?
|
| Fibromyalgia | 1 | 2009 | 15 | 0.070 |
Why?
|
| Female | 12 | 2014 | 34459 | 0.070 |
Why?
|
| Isoenzymes | 2 | 2000 | 130 | 0.070 |
Why?
|
| Peritonitis | 1 | 2009 | 43 | 0.070 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 24 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 2 | 2008 | 869 | 0.070 |
Why?
|
| RANK Ligand | 1 | 2008 | 23 | 0.070 |
Why?
|
| Anilides | 1 | 2007 | 18 | 0.070 |
Why?
|
| Cell Separation | 3 | 2008 | 148 | 0.070 |
Why?
|
| Middle Aged | 8 | 2008 | 18518 | 0.070 |
Why?
|
| Prostaglandin Antagonists | 1 | 2007 | 2 | 0.060 |
Why?
|
| Phorbol Esters | 1 | 2007 | 4 | 0.060 |
Why?
|
| Drug Design | 2 | 2007 | 139 | 0.060 |
Why?
|
| Chromatography, Thin Layer | 1 | 2007 | 16 | 0.060 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2007 | 42 | 0.060 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 52 | 0.060 |
Why?
|
| Edema | 1 | 2007 | 42 | 0.060 |
Why?
|
| Alanine | 1 | 2007 | 49 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 17 | 0.060 |
Why?
|
| Interleukin-1alpha | 1 | 2007 | 25 | 0.060 |
Why?
|
| Blood Platelets | 3 | 1996 | 108 | 0.060 |
Why?
|
| Cartilage | 1 | 2007 | 35 | 0.060 |
Why?
|
| Cell Culture Techniques | 1 | 2008 | 195 | 0.060 |
Why?
|
| Sulfhydryl Compounds | 1 | 2007 | 52 | 0.060 |
Why?
|
| Liver | 2 | 2002 | 879 | 0.060 |
Why?
|
| Lipopolysaccharides | 2 | 2001 | 625 | 0.060 |
Why?
|
| Aspirin | 1 | 1987 | 172 | 0.060 |
Why?
|
| Leukocytes | 1 | 2007 | 110 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 279 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2008 | 223 | 0.060 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 159 | 0.060 |
Why?
|
| Signal Transduction | 4 | 1999 | 3171 | 0.060 |
Why?
|
| Chronic Disease | 4 | 2007 | 745 | 0.060 |
Why?
|
| Stem Cells | 1 | 2008 | 278 | 0.060 |
Why?
|
| Transcription Factors | 2 | 2004 | 1561 | 0.060 |
Why?
|
| Adult | 8 | 2008 | 17595 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 108 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2004 | 15 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 812 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2007 | 506 | 0.050 |
Why?
|
| Cytokines | 3 | 2008 | 967 | 0.050 |
Why?
|
| Joints | 1 | 2003 | 33 | 0.050 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2003 | 20 | 0.050 |
Why?
|
| Annexin A5 | 1 | 2003 | 20 | 0.050 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 34 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2005 | 214 | 0.050 |
Why?
|
| CD3 Complex | 2 | 2008 | 63 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2005 | 665 | 0.050 |
Why?
|
| Cyclic AMP | 2 | 1989 | 144 | 0.050 |
Why?
|
| Behavior | 1 | 2003 | 36 | 0.050 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2002 | 1 | 0.050 |
Why?
|
| Felty Syndrome | 1 | 2002 | 2 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2003 | 108 | 0.050 |
Why?
|
| Hemochromatosis | 1 | 2002 | 8 | 0.050 |
Why?
|
| Cell Line | 1 | 2007 | 2032 | 0.050 |
Why?
|
| Scleroderma, Systemic | 1 | 2002 | 20 | 0.050 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2002 | 24 | 0.050 |
Why?
|
| Lymphocytes | 2 | 1995 | 209 | 0.050 |
Why?
|
| RNA Stability | 1 | 2003 | 104 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 1995 | 463 | 0.040 |
Why?
|
| Caspases | 1 | 2003 | 176 | 0.040 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2002 | 13 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 1994 | 749 | 0.040 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 31 | 0.040 |
Why?
|
| Sjogren's Syndrome | 1 | 2002 | 25 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 401 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2007 | 2170 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 50 | 0.040 |
Why?
|
| Phagocytes | 2 | 1995 | 52 | 0.040 |
Why?
|
| Immunity | 1 | 1982 | 107 | 0.040 |
Why?
|
| Lipids | 2 | 1996 | 330 | 0.040 |
Why?
|
| Fatty Acids, Essential | 2 | 1993 | 8 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 426 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2001 | 85 | 0.040 |
Why?
|
| Biopsy | 1 | 2002 | 464 | 0.040 |
Why?
|
| Phenotype | 1 | 2005 | 1236 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2001 | 115 | 0.040 |
Why?
|
| Membrane Lipids | 2 | 1993 | 25 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1982 | 186 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2000 | 146 | 0.040 |
Why?
|
| Osteoarthritis, Knee | 1 | 2005 | 401 | 0.040 |
Why?
|
| Aged | 5 | 2008 | 15155 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2000 | 328 | 0.040 |
Why?
|
| Uric Acid | 2 | 1989 | 47 | 0.040 |
Why?
|
| Linoleic Acids | 2 | 1988 | 9 | 0.030 |
Why?
|
| Cyclooxygenase 1 | 1 | 1998 | 6 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 1998 | 12 | 0.030 |
Why?
|
| Freund's Adjuvant | 1 | 1998 | 14 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 1999 | 180 | 0.030 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1997 | 4 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 1997 | 14 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 1998 | 106 | 0.030 |
Why?
|
| Safflower Oil | 1 | 1997 | 1 | 0.030 |
Why?
|
| Sunflower Oil | 1 | 1997 | 5 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1998 | 70 | 0.030 |
Why?
|
| Flax | 1 | 1997 | 7 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1998 | 111 | 0.030 |
Why?
|
| Helianthus | 1 | 1997 | 6 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2007 | 344 | 0.030 |
Why?
|
| Binding Sites | 2 | 2014 | 923 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 382 | 0.030 |
Why?
|
| Placebos | 1 | 1996 | 73 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2001 | 645 | 0.030 |
Why?
|
| Phospholipases A2 | 2 | 1986 | 15 | 0.030 |
Why?
|
| Kinetics | 1 | 1997 | 760 | 0.030 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 1995 | 7 | 0.030 |
Why?
|
| Acute Disease | 2 | 1994 | 665 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 1995 | 74 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1995 | 15 | 0.030 |
Why?
|
| Docosahexaenoic Acids | 1 | 1995 | 31 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 1635 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2014 | 18 | 0.030 |
Why?
|
| Skin | 1 | 1998 | 436 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2014 | 114 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 1995 | 180 | 0.030 |
Why?
|
| Mice, Inbred NZB | 2 | 1983 | 21 | 0.020 |
Why?
|
| Alprostadil | 1 | 1993 | 6 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1994 | 626 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 1993 | 413 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 343 | 0.020 |
Why?
|
| Time Factors | 2 | 1997 | 3780 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2007 | 5684 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2014 | 234 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1993 | 178 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 112 | 0.020 |
Why?
|
| Phagocytosis | 2 | 1988 | 257 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 1991 | 61 | 0.020 |
Why?
|
| SRS-A | 1 | 1990 | 2 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 152 | 0.020 |
Why?
|
| Leukotriene B4 | 1 | 1990 | 12 | 0.020 |
Why?
|
| Blood Cells | 1 | 1990 | 17 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1990 | 71 | 0.020 |
Why?
|
| Pregnancy | 1 | 1997 | 2411 | 0.020 |
Why?
|
| Indomethacin | 1 | 1989 | 23 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 1994 | 1570 | 0.020 |
Why?
|
| Oenothera biennis | 1 | 1988 | 1 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 150 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2008 | 8 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1991 | 710 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2008 | 37 | 0.020 |
Why?
|
| CD28 Antigens | 1 | 2008 | 62 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2008 | 194 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2008 | 132 | 0.020 |
Why?
|
| Linoleic Acid | 1 | 1987 | 19 | 0.020 |
Why?
|
| Phospholipids | 1 | 1987 | 81 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1994 | 3340 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2007 | 111 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 137 | 0.020 |
Why?
|
| Telomere | 1 | 2007 | 59 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2007 | 415 | 0.010 |
Why?
|
| Ligands | 1 | 2007 | 414 | 0.010 |
Why?
|
| Adolescent | 1 | 1996 | 6371 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1985 | 39 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2007 | 672 | 0.010 |
Why?
|
| Diet | 1 | 1989 | 540 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2007 | 793 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 1595 | 0.010 |
Why?
|
| Arthus Reaction | 1 | 1983 | 1 | 0.010 |
Why?
|
| Dermatitis, Contact | 1 | 1983 | 12 | 0.010 |
Why?
|
| Chemistry | 1 | 1983 | 31 | 0.010 |
Why?
|
| Granuloma | 1 | 1983 | 43 | 0.010 |
Why?
|
| Crystallization | 1 | 1983 | 97 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1983 | 96 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1150 | 0.010 |
Why?
|
| Exudates and Transudates | 2 | 1973 | 12 | 0.010 |
Why?
|
| Bone Resorption | 1 | 1983 | 46 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 1994 | 5832 | 0.010 |
Why?
|
| Sheep | 1 | 1983 | 194 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2007 | 1161 | 0.010 |
Why?
|
| Rabbits | 1 | 1983 | 343 | 0.010 |
Why?
|
| Cattle | 1 | 1983 | 320 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 1982 | 17 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 1638 | 0.010 |
Why?
|
| Nephritis | 1 | 1982 | 11 | 0.010 |
Why?
|
| Dogs | 1 | 1983 | 327 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 1982 | 42 | 0.010 |
Why?
|
| Receptors, Drug | 1 | 2001 | 4 | 0.010 |
Why?
|
| Diglycerides | 1 | 2001 | 24 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2001 | 44 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2001 | 167 | 0.010 |
Why?
|
| Base Sequence | 2 | 1995 | 1332 | 0.010 |
Why?
|
| Biomarkers | 1 | 2007 | 1506 | 0.010 |
Why?
|
| Adipocytes | 1 | 2003 | 276 | 0.010 |
Why?
|
| Glioma | 1 | 2001 | 101 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 1980 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 606 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 690 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2001 | 398 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1982 | 566 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1997 | 19 | 0.010 |
Why?
|
| DNA | 1 | 1982 | 853 | 0.010 |
Why?
|
| Inositol Phosphates | 1 | 1997 | 17 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1995 | 14 | 0.010 |
Why?
|
| Consensus Sequence | 1 | 1995 | 30 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1997 | 372 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1995 | 53 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1995 | 302 | 0.010 |
Why?
|
| Calcium | 1 | 1997 | 587 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1973 | 18 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1973 | 34 | 0.010 |
Why?
|
| Glucuronidase | 1 | 1973 | 25 | 0.010 |
Why?
|
| Adrenalectomy | 1 | 1973 | 26 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1973 | 50 | 0.010 |
Why?
|
| Adrenal Glands | 1 | 1973 | 36 | 0.010 |
Why?
|
| Tarsal Joints | 1 | 1973 | 4 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 1973 | 20 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 875 | 0.010 |
Why?
|
| Tibia | 1 | 1973 | 76 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1973 | 128 | 0.010 |
Why?
|
| Cartilage, Articular | 1 | 1973 | 79 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 1590 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 242 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 516 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1995 | 911 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1973 | 424 | 0.000 |
Why?
|